Technical Analysis for HOWL - Werewolf Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 4.79 | 1.48% | 0.07 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 1.48% | |
| Narrow Range Bar | Range Contraction | 1.48% | |
| Inside Day | Range Contraction | 1.48% | |
| Wide Bands | Range Expansion | 1.48% | |
| Oversold Stochastic | Weakness | 1.48% | |
| Wide Bands | Range Expansion | -1.84% | |
| Oversold Stochastic | Weakness | -1.84% | |
| Lower Bollinger Band Walk | Weakness | -1.24% | |
| Wide Bands | Range Expansion | -1.24% | |
| Gapped Up | Strength | -1.24% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | 31 minutes ago |
| 3x Volume Pace | 31 minutes ago |
| Down 3% | 31 minutes ago |
| Down 2 % | 31 minutes ago |
| Down 1% | 31 minutes ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/08/2024
Werewolf Therapeutics, Inc. Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Health Sciences Treatment Of Cancer Cancer Immunotherapy Lymphoma Hematologic Malignancies Advanced Solid Tumors Metastatic Solid Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.1939 |
| 52 Week Low | 1.5735 |
| Average Volume | 178,014 |
| 200-Day Moving Average | 4.10 |
| 50-Day Moving Average | 5.85 |
| 20-Day Moving Average | 5.73 |
| 10-Day Moving Average | 5.16 |
| Average True Range | 0.49 |
| RSI (14) | 35.90 |
| ADX | 19.25 |
| +DI | 13.73 |
| -DI | 25.27 |
| Chandelier Exit (Long, 3 ATRs) | 5.43 |
| Chandelier Exit (Short, 3 ATRs) | 5.86 |
| Upper Bollinger Bands | 7.08 |
| Lower Bollinger Band | 4.38 |
| Percent B (%b) | 0.13 |
| BandWidth | 47.27 |
| MACD Line | -0.33 |
| MACD Signal Line | -0.20 |
| MACD Histogram | -0.1276 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.08 | ||||
| Resistance 3 (R3) | 5.12 | 5.04 | 5.02 | ||
| Resistance 2 (R2) | 5.04 | 4.95 | 5.02 | 5.00 | |
| Resistance 1 (R1) | 4.88 | 4.89 | 4.84 | 4.84 | 4.98 |
| Pivot Point | 4.80 | 4.80 | 4.78 | 4.78 | 4.80 |
| Support 1 (S1) | 4.64 | 4.71 | 4.60 | 4.60 | 4.46 |
| Support 2 (S2) | 4.56 | 4.65 | 4.54 | 4.44 | |
| Support 3 (S3) | 4.40 | 4.56 | 4.42 | ||
| Support 4 (S4) | 4.36 |
